Hepatitis C is a viral infection that can cause long-term liver damage, cirrhosis and liver cancer if left untreated. Modern direct-acting antiviral (DAA) medicines have significantly changed hepatitis C treatment, with many patients able to achieve viral clearance following a relatively short course of oral therapy. The World Health Organization (WHO) reports that DAAs can cure more than 95% of people with hepatitis C.
Two important antiviral medicines associated with hepatitis C treatment are ledipasvir and sofosbuvir. Although they are often discussed together, they work in different ways against the hepatitis C virus (HCV).
What Is Ledipasvir?
Ledipasvir is an antiviral medicine that belongs to the NS5A inhibitor class. It interferes with the HCV NS5A protein, which plays an important role in viral replication.
Ledipasvir is particularly known for its use in combination with sofosbuvir. Rather than being viewed as a replacement for sofosbuvir, ledipasvir is generally used as part of a combination regimen.
The combination of ledipasvir and sofosbuvir is available as a fixed-dose oral treatment. The FDA's prescribing information identifies ledipasvir as an HCV NS5A inhibitor.
What Is Sofosbuvir?
Sofosbuvir is an HCV antiviral belonging to the nucleotide analogue NS5B polymerase inhibitor class.
The NS5B polymerase is essential for HCV replication. By targeting this viral enzyme, sofosbuvir interferes with the virus's ability to reproduce.
Sofosbuvir is used in several HCV treatment combinations and has become an important component of DAA-based therapy.
Ledipasvir vs Sofosbuvir: What Is the Difference?
The main difference is their mechanism of action and viral target.
| Feature | Ledipasvir | Sofosbuvir |
|---|---|---|
| Drug class | NS5A inhibitor | NS5B nucleotide polymerase inhibitor |
| Main target | HCV NS5A protein | HCV NS5B polymerase |
| Primary role | Blocks viral replication and other NS5A functions | Inhibits viral RNA replication |
| Common use | Used in combination with other antivirals | Used in combination with other antivirals |
| Combination | Commonly combined with sofosbuvir | Commonly combined with ledipasvir or other DAAs |
Because the medicines target different parts of the HCV replication process, combining them can provide complementary antiviral activity.
How Do Ledipasvir and Sofosbuvir Work Together?
The best-known combination is ledipasvir/sofosbuvir, a fixed-dose DAA regimen.
The FDA describes the combination as containing ledipasvir 90 mg and sofosbuvir 400 mg in the approved tablet formulation.
The two medicines attack HCV through different mechanisms:
- Ledipasvir targets the NS5A protein.
- Sofosbuvir targets the NS5B polymerase.
- Together, they interfere with different stages of viral replication.
This combination was an important development in interferon-free hepatitis C treatment. WHO guidance has previously included ledipasvir/sofosbuvir among recommended regimens for certain HCV genotypes.
Is Ledipasvir or Sofosbuvir Better?
Ledipasvir and sofosbuvir are not simply alternatives to one another. They have different targets and are frequently used together.
The appropriate hepatitis C treatment depends on factors such as:
- HCV genotype
- Presence or absence of cirrhosis
- Previous HCV treatment
- Other medical conditions
- Kidney and liver function
- Potential drug interactions
- Current national treatment guidelines
Current WHO guidance emphasizes pan-genotypic DAA regimens for hepatitis C, while specific treatment selection should be based on the patient's clinical circumstances and applicable guidelines.
Therefore, patients should not choose between ledipasvir and sofosbuvir independently. A qualified healthcare professional should determine the appropriate regimen.
Ledipasvir and Sofosbuvir for Hepatitis C Treatment
Ledipasvir/sofosbuvir has been studied extensively in people with hepatitis C, particularly those with certain genotypes. Earlier AASLD/IDSA guidance documents evidence supporting its use in specific patient populations, including selected genotype 1 and genotype 4 infections.
However, hepatitis C treatment recommendations have evolved as newer pan-genotypic therapies have become available. For this reason, information about older or genotype-specific regimens should be interpreted alongside current national and international guidelines.
What Should Patients Know Before Treatment?
Before starting hepatitis C medication, healthcare professionals generally evaluate the patient's HCV status and medical history. Testing may include confirmation of active HCV infection, assessment of liver disease and review of other medicines.
Drug interactions are particularly important because some medicines and supplements can affect antiviral treatment.
Patients should also follow the prescribed treatment schedule and avoid stopping therapy without medical advice.
Access to Hepatitis C Medicines
The availability of generic direct-acting antivirals has helped expand access to hepatitis C treatment in many countries. WHO reports that generic versions have contributed to substantial reductions in treatment prices in numerous low- and middle-income countries.
For healthcare providers, pharmacies, hospitals and pharmaceutical distributors sourcing hepatitis C medicines internationally, important considerations include product authorization, supplier documentation, applicable import requirements, storage conditions and local regulatory requirements.
Frequently Asked Questions
Is ledipasvir the same as sofosbuvir?
No. Ledipasvir and sofosbuvir are different antiviral medicines that target different HCV proteins. They can be combined into a single fixed-dose treatment.
What does ledipasvir do?
Ledipasvir is an NS5A inhibitor that interferes with functions required for hepatitis C virus replication.
What does sofosbuvir do?
Sofosbuvir is an NS5B polymerase inhibitor that interferes with HCV RNA replication.
Can ledipasvir and sofosbuvir be taken together?
Yes. The medicines are available together as a fixed-dose combination for appropriate patients. Treatment selection and duration should be determined according to current clinical guidelines and individual patient factors.
Does everyone with hepatitis C use ledipasvir and sofosbuvir?
No. Current hepatitis C treatment depends on genotype, cirrhosis status, previous treatment and other clinical considerations. WHO currently recommends pan-genotypic DAA treatment approaches for chronic HCV.
Can hepatitis C be cured?
Yes. Modern DAA treatments can cure more than 95% of people with hepatitis C when appropriately prescribed and completed.
Conclusion
Ledipasvir and sofosbuvir play different but complementary roles in hepatitis C treatment. Ledipasvir targets NS5A, while sofosbuvir targets the NS5B polymerase. Their combination has been an important DAA treatment option for specific HCV populations.
Because hepatitis C treatment recommendations continue to evolve, patients and healthcare professionals should refer to current national and international guidelines when selecting therapy. WHO's 2026 consolidated guidance provides the latest global framework for hepatitis B and C prevention, testing, treatment and monitoring.
Important: This article is for educational purposes and does not replace medical advice, diagnosis or prescribing guidance. Patients should consult a qualified healthcare professional before starting, changing or stopping hepatitis C treatment.